Sign in
Taking people in United StatesPhase 4

Acceptability and Feasibility of Extended-Release Subcutaneous Buprenorphine on a Mobile Pharmacy Clinic

Key facts

Who runs it
Yale University
Where
New Haven, United StatesSee the site
Trial code
Status
Recruiting
Phase
Phase 4
People taking part
60 people, planned
Started
23 Sept 2026
Expected to end
Feb 2027
Type of study
Interventional
Treatments tested
  • Buprenorphine
Record updated
9 October 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Able to provide written informed consent in English or Spanish
  • Current or history of DSM-5 moderate-to-severe OUD per Rapid Opioid Use Disorder Assessment (ROUDA)
  • Not planning to move out of state or to new location during study enrollment

Who cannot take part

  • Medical or psychiatric disorders making participation unsafe or regular follow-up unlikely, (such as suicidal ideation or pre-existing moderate to severe hepatic impairment)
  • Allergy, hypersensitivity, or medical contraindication to medication (the BRIXADI needle cap is synthetically derived from natural rubber latex which may cause allergic reactions in persons with latex-sensitivity)
  • Persons who are pregnancy
  • People who show violent or threatening behavior toward staff and/or others

This trial is currently available in United States.

  • Yale School of MedicineNew Haven, United StatesContact: Angela Di Paola, PhDTaking people

About the trial

What the trial wants to find out

This exploratory project will assess the acceptability and feasibility of monthly extended-release subcutaneous buprenorphine (BRIXADI; XR-B) to treat opioid use disorder (OUD) among persons in the community receiving care on a mobile pharmacy clinic (MPC).

Read full original descriptionShow less

Participants who are interested in initiating monthly or weekly injections of subcutaneous XR-B (BRIXADI) as a treatment for their OUD will be enrolled in a 6-month study assessing the acceptability and feasibility of receiving XR-B on an MPC.

The group in the trial

  • BuprenorphineTreatment being tested

    Participants will be offered weekly or monthly Buprenorphine injections

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Acceptability and Feasibility of Extended-Release Subcutaneous Buprenorphine on a Mobile Pharmacy Clinic: A Pilot Study
Record updated
9 October 2026